Alterity Therapeutics Files Application for Quotation of Securities

Alterity Therapeutics Limited, a development-stage biotechnology company, filed a Form 6-K on September 8, 2026, with the SEC. The filing primarily serves as an application for the quotation of securities (ATH) on the relevant exchange. This administrative filing incorporates the new securities application by reference into several of the company\'s existing Registration Statements on Form S-8 and Form F-3. The document was signed by Julian Babarczy, the Chairman of the Board. While the filing indicates an application for the quotation of securities, it does not provide specific details regarding the number of shares, pricing, or the specific purpose of the issuance beyond the standard regulatory requirement for listing. This type of filing is common for companies managing equity incentive plans or shelf registration statements to ensure new shares are properly registered and tradable. No clinical trial updates or other material business developments were disclosed in this specific report.